LGM
FOLD

Logos Global Management’s Amicus Therapeutics FOLD Stock Holding History

Logos Global Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-625,000
Closed -$7.22M – 55
2021
Q4 		$7.22M Buy
+625,000
New +$6.97M 0.74% 32
2020
Q2 		– Sell
-446,882
Closed -$4.13M – 54
2020
Q1 		$4.13M Buy
+446,882
New +$4.25M 1.57% 26

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Logos Global Management's FOLD Position: Q1 2022 in Review

Logos Global Management sold out of Amicus Therapeutics (FOLD) in Q1 2022, closing a stake of 625,000 shares — an estimated $7.22M sold.

Logos Global Management first reported a position in FOLD in Q1 2020 and held it in 2 quarters. The position peaked at $7.22M in Q4 2021. 217 funds tracked by Wall St. Rank hold FOLD as of Q1 2022.

  • Logos Global Management reported no remaining Amicus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Logos Global Management sold 625,000 Amicus Therapeutics shares in Q1 2022, an estimated $7.22M.
  • Logos Global Management first reported a position in Amicus Therapeutics in Q1 2020 and held it in 2 quarters.
  • Logos Global Management's Amicus Therapeutics position peaked at $7.22M in Q4 2021.
  • 217 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2022.

Based on Logos Global Management's 13F filing for Q1 2022, filed 16 May 2022.